Antimicrobial Stewardship and the Impact of MICs on Patient Outcomes

Managing the Development of Antimicrobial Resistance

Antimicrobial resistance continues to be a significant global health threat. Delayed or inaccurate lab results could not only contribute to the further development of resistance but could lead to the mistreatment and potential mortality of patients with multi-drug-resistant infections.

The lack of successful antimicrobial and diagnostic stewardship programs can exacerbate the overuse of broad-spectrum and toxic antibiotics. Limited access to diagnostics that can deliver accurate minimum inhibitory concentration (MIC) results for highly effective new-generation drugs can lead to failed therapy, adverse effects, increased costs, and increased potential for patient mortality.

The webinar will review the positive impact effective antimicrobial stewardship can have on managing the development of resistance. The presenter will also discuss how dosing new drugs based on accurate MIC data can help reduce costs and improve patient outcomes.

Learning Objectives

This webinar will help you:

• Examine the ways in which antibiotic stewardship can help healthcare providers deliver optimal care and reduce unnecessary antibiotic exposure risk
• Explain how using institutional data can guide empiric therapy for multi-drug-resistant infections
• Discuss the importance of receiving timely and accurate organism identification and susceptibility data when conducting daily antibiotic stewardship activities and treating aggressive, complicated infections
• Describe how effective stewardship can reduce the development of resistance and improve patient outcomes

Watch On Demand   Download Slides (PDF, 1.1 MB)

Fisher Healthcare is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.™ Program. One P.A.C.E.™ credit-hour will be provided for this complimentary basic level program.

Jerod Nagel, PharmD, BCIDP

Jerod Nagel is a clinical pharmacist; an infectious diseases clinical assistant professor; the director of the infectious disease residency; and the pharmacy team lead for the Infectious Diseases and Antimicrobial Stewardship Programs for the University of Michigan Health Systems. Much of Dr. Nagel’s research has focused on how antimicrobial stewardship programs can improve patient outcomes and has included several risk-factor studies leading to over 85 peer-reviewed publications.

Nagel has served as a leader for several organizations, including the Antimicrobial Stewardship in Cancer Consortium; the antimicrobial subcommittee of the Infectious Disease Society of America; and the Vizient Antimicrobial Stewardship committee. He has also been named the Society of Infectious Disease Pharmacists Clinician of the Year.